Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis
Review of 4RCTs (n=7953) concludes insufficient evidence to determine effect of dual v triple therapy on all-cause mortality, CV mortality, MI, stroke or in-stent thrombosis. However, high-certainty evidence shows dual therapy is linked to reduced risk for major bleeding.
Source:
Annals of Internal Medicine
SPS commentary:
The review included RCTs evaluating safety and effectiveness of dual therapy (direct oral anticoagulant [DOAC] plus P2Y12 inhibitor) versus triple therapy (vitamin K antagonist plus aspirin and P2Y12 inhibitor) in patients with nonvalvular atrial fibrillation after percutaneous coronary.